Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer

Thrombosis Research

Volumn 125, Issue 3, 2010, Pages

  Sierko, Ewa ^a,b   Wojtukiewicz, Marek Z ^a,b   Zawadzki, Roman ^a   Zimnoch, Lech ^a   Kisiel, Walter ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Regional Comprehensive Cancer Center in Bialystok   (Poland)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulation inhibitor; Colon cancer; Protein C; Protein S; Rectal cancer; Thrombomodulin

Indexed keywords

PROTEIN C; PROTEIN S; THROMBOMODULIN;

ADULT; ARTICLE; CANCER CELL; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADULT; ANTICOAGULANTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTEIN C; PROTEIN S; THROMBOMODULIN;

EID: 76949094367     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.09.011     Document Type: Article

References (55)

1. Hillen H.F.P. Thrombosis in cancer patients. Ann Oncol 11 Supl. 3 (2000) 273-276
2. Casillas S., and Nicholson J.D. Aortic thrombosis after low anterior resection for rectal cancer: report of a case. Dis Colon Rectum 45 (2002) 829-832
3. Bergqvist D., and Lindblad B. Thromboembolic problems in colorectal cancer surgery. Scand J Gastroenterol Suppl. 149 (1988) 74-81
4. Iversen L.H., and Thorlacius-Ussing O.O. Relationship of coagulation test abnormalities to tumor burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 87 (2002) 402-408
5. Lee F.Y., Chu W., Chan R., Leung Y.F., Liu K.H., Ng S.M., et al. Incidence of deep vein thrombosis after colorectal surgery in a Chinese population. ANZ J Surg 71 (2001) 637-640
6. Longo W.E., Virgo K.S., Johnson F.E., Wade T.P., Vernava A.M., Phelan M.A., et al. Outcome after proctectomy for rectal cancer in Department of Veterans Affairs Hospitals: a report from the National Surgical Quality Improvement Program. Ann Surg 228 (1998) 64-70
7. Iversen L.H., Okholm M., and Thorlacius-Ussing O.O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease - a preliminary study. Thromb Haemost 76 (1996) 523-528
8. Abbasciano V., Guerra S., Reali M.G., and Guglielmini C. Pre- and postsurgery activation of blood coagulation in gastric and large bowel cancers: diagnostic, therapeutic and prognostic hints. Oncology 47 (1990) 261-266
9. Wojtukiewicz M.Z., Zacharski L.R., Moritz T.E., Hur K., Edwards R.L., and Rickles F.R. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagul Fibrinol 3 (1992) 429-437
10. Esmon C.T. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 32 Suppl 1 (2006) 49-60
11. Esmon C.T. Role of coagulation inhibitors in inflammation. Thromb Haemost 86 (2001) 51-56
12. Esmon C.T. The endothelial cell protein C receptor. Thromb Haemost 83 (2000) 639-643
13. Bombeli T., Mueller M., and Haeberi A. Anticoagulant properties of vascular endothelium. Thromb Haemost 77 (1997) 408-423
14. Dahlbäck B., and Villoutreix B.O. Molecular recognition in the protein C anticoagulant pathway. J Throm Haemost 1 (2003) 1525-1534
15. Ellis C.N., Boggs H.W., Slagle G.W., Cole P.A., Coyle D.J., and Blakemore W.S. Protein C activity, stage of disease, and vascular thrombosis in colon carcinoma. Am J Surg 163 (1992) 78-81
16. Green D., Maliekel K., Sushko E., Akhtar R., and Soff G.A. Activated-protein-C resistance in cancer patients. Haemostasis 27 (1997) 112-118
17. De Lucia D., De Vita F., Orditura M., Renis V., Belli A., Conte M., et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori. 83 (1997) 948-952
18. Paspatis G.A., Sfyridaki A., Papanikolaou N., Triantafyllou K., Livadiotaki A., Kapsoritakis A., et al. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb 32 (2002) 2-7
19. Wojtukiewicz M.Z., Zacharski L.R., Memoli V.A., Kisiel W., Kudryk B.J., Rousseau S.M., et al. Indirect activation of blood coagulation in colon cancer. Thromb Haemost 62 (1989) 1062-1066
20. Sierko E., Tokajuk P., Butkiewicz A., Sulkowski S., Zimnoch L., and Wojtukiewicz M.Z. Expression of blood coagulation components in loco in colon cancer. Pol Merk Lek 17 (2005) 176-179 [Article in Polish]
21. Hsu S., Raine L., and Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29 (1981) 577-580
22. Remmele W., and Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologie 8 (1987) 138-140
23. Zacharski L.R., Wojtukiewicz M.Z., Costantini V., Ornstein D.L., and Memoli V.A. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 18 (1992) 104-116
24. Wojtukiewicz M.Z., Sierko E., and Rak J. Contribution of hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 30 (2004) 5-20
25. Wojtukiewicz M.Z., Sierko E., and Kisiel W. The role of hemostatic system inhibitors in malignancy. Semin Thromb Hemost 33 (2007) 621-641
26. Wojtukiewicz M.Z., Zacharski L.R., Memoli V.A., Kisiel W., Kudryk B.J., Rousseau S.M., et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 65 (1990) 481-485
27. Wojtukiewicz M.Z., Sierko E., Zacharski L.R., and Zimnoch L. and Kisiel. Tissue factor dependent coagulation activation and impaired fibrinolysis in loco in gastric cancer. Semin Thromb Hemost 29 (2003) 291-299
28. Wojtukiewicz M.Z., Rucińska M., Zacharski L.R., Kozłowski L., Zimnoch L., Piotrowski Z., et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 86 (2001) 1416-1420
29. Wojtukiewicz M.Z., Zacharski L.R., Memoli V.A., Kisiel W., Kudryk B.J., Rousseau S.M., et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 93 (1990) 516-521
30. Wojtukiewicz M.Z., Zacharski L.R., Memoli V.A., Kisiel W., Kudryk B.J., Moritz T.E., et al. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 67 (1991) 1377-1381
31. Uchiba M., Okajima K., Oike Y., Ito Y., Fukudome K., Isobe H., et al. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res 95 (2004) 34-41
32. Cheng T., Liu D., and Griffin J.H. e Fernández JA, Castellino F, Rosen ED, Fukudome K and Zlokovic BV. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 9 (2003) 338-342
33. Feistritzer C., and Riewald M. Endothelial barrier protection by activated protein C through PAR-1-dependent sphingosine1-phosphate receptor-1 crossactivation. Blood 105 (2005) 3178-3184
34. Guo H., Liu D., Gelbard H., Fernández J.A., Castellino F., Rosen E.D., et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 2. Neuron 41 (2004) 563-572
35. Tang W., TG B.-J., Renaud C., Walz D.A., and Honn K.V. Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 55 (1995) 698-704
36. Darmoul D., Gratio V., Devaud H., Lehy T., and Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 cell induces cell proliferation and motility in human colon cancer cells. Am J Pathol 162 (2003) 1503-1513
37. Even-Ram S., Uziely B., Cohen P., Grisaru-Granovsky S., Maoz M., Ginzburg Y., et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4 (1998) 909-914
38. Pleyer L., Went P., Russ G., Prinz E., Faber V., Röwert H.J., et al. Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C. Wien Klin Wochenschr 119 (2007) 254-258
39. Beaulieu L.M., and Church F.C. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res 313 (2007) 677-687
40. Nguyen M., Arkell J., and Jackson C.J. Activated protein C directly activates human endothelial gelatinase A. J Biol Chem 275 (2000) 9095-9098
41. Papadopoulou S., Scorilas A., Arnogianaki N., Papapanayiotou B., Tzimogiani A., Agnantis N., et al. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumor Biol 22 (2001) 383-389
42. Tsuneyoshi N., Fukudome K., Horiguchi S., Ye X., Matsuzaki M., Toi M., et al. Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb Haemost 85 (2001) 356-361
43. Scheffer G.L., Flens M.J., Hageman S., Izquierdo M.A., Shoemaker R.H., and Scheper R.J. Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer 38 (2002) 1535-1542
44. Phillips D.J., Greengard J.S., Fernandez J.A., Ribeiro M., Evatt B.L., Griffin J.H., et al. Protein S, an antithrombotic factor, is synthesized and released by neural tumor cells. J Neurochem 61 (1993) 344-347
45. Wimmel A., Rohner I., Ramaswamy A., Heidtmann H.H., Seitz R., Kraus M., et al. Synthesis and secrection of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells. Cancer 86 (1999) 43-49
46. Liu D., Guo H., Griffin J.H., Fernandez J.A., and Zlokovic B.V. Protein S confers neuronal protection during ischemic/hypoxic injury in mice. Circulation 107 (2003) 1791-1796
47. Anderson H.A., Maylock C.A., Williams J.A., Paweletz C.P., Shu H., and Shacter E. Serum-derived protein S binds to phosphatidilserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 4 (2003) 87-91
48. Ogawa H., Yonezawa S., Maruyama I., Matsushita Y., Tezuka Y., Toyoyama H., et al. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett 149 (2000) 95-103
49. Hamatake M., Ishida T., Akazawa K., Mitsudomi, and Sugimachi K. Prognostic value and pathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. Clin Cancer Res 2 (1996) 763-766
50. Tezuka Y., Yonezawa S., Maruyama I., Matsushita Y., Shimizu T., Obama H., et al. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. Cancer Res 55 (1995) 4196-4200
51. Tamura A., Hebisawa A., Hayashi K., Sagara Y., Fukushima K., Kurashima A., et al. Prognostic significance of thrombomodulin expression and vascular invasion in stage I squamous cell carcinoma of the lung. Lung Cancer 34 (2001) 375-382
52. Kim S.J., Shiba E., Ischi H., Inoue T., Taguchi T., Tanji Y., et al. Thrombomodulin is a new biological and prognostic marker for breast cancer: an Immunohistochemical study. Anticancer Res 17 (1997) 2319-2323
53. Hanly A.M., Redmond M., Winter D.C., Brophy S., Deasy J.M., Bouchier-Hayes D.J., et al. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer 94 (2006) 1320-1325
54. Furuta J., Kaneda A., Umebayashi Y., Otsuka F., Sugimura T., and Ushijama T. Silencing of the thrombomodulin gene in human malignant melanoma. Melanoma Res 15 (2005) 15-20
55. Zhang Y., Weiler-Guettler H., Chen J., Wilhelm O., Deng Y., Qiu F., et al. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest 101 (1998) 1301-1309